Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 375 results
A minimalist representation of an antibody structure in flat design.

Oct 2, 2026

‘We’ve been taking our time’: Buzzy AI biotech Xaira reveals antibody platform, first taste of pipeline

Xaira Therapeutics, which made headlines in 2024 with a remarkable $1 billion funding, has recently unveiled details about its generative AI antibody design platform, X-Design, and the early stages of its drug pipeline.CEO Marc Tessier-Lavigne emphasized that X-Design is pivotal for developing ready-to-use antibodies and supports a broader therapeutic pipeline. The company is employing a comprehensive approach to drug discovery, which includes identifying targets, creating drugs, and pinpointing
Press release cover image

Oct 2, 2026

Quotient Sciences and Acesion Pharma Announce Collaboration on AI-Enhanced Formulation Development to Advance Atrial Fibrillation Pipeline

New AI-enhanced solution helps identify promising drug formulations, compressing early clinical decision-making for new treatmentsNOTTINGHAM, England, Oct. 2, 2026 /PRNewswire/ -- Quotient Sciences, a global integrated CRDMO (contract research, development and manufacturing organization), and Acesion Pharma, a Copenhagen-based biotech company developing treatments for cardiac arrhythmia, today announced a new collaboration applying Quotient Sciences' AI-enhanced formulation development solution
Press release cover image

Oct 1, 2026

Avimer Bio and CNIO Advance Protein Cage Design for Targeted Medicine

Avimer Bio and CNIO announce JACS publication detailing computational methods to build self-assembling protein cages with atomic precision for targeted medicine.SAN DIEGO, Oct. 1, 2026 /PRNewswire/ -- Avimer Bio, in collaboration with structural biologists at the Spanish National Cancer Research Centre (CNIO), announced a new publication in the Journal of the American Chemical Society (JACS) describing advances in building self-assembling protein cages with atomic precision. The work addresses a
Press release cover image

Oct 1, 2026

Talus Bio Launches Ptarmigan-1, the First Structure-Free AI Model for Proteome-Wide Drug Discovery

Available now through a public portal, Ptarmigan-1 is the first AI model to accurately predict how small molecules bind to all proteins, including disordered and historically undruggable targets, without modeling a 3D structureSEATTLE--(BUSINESS WIRE)--Talus Bioscience, Inc. (“Talus Bio”), an AI-native therapeutics company, today released Ptarmigan-1, the first structure-free model that can accurately predict small molecule binding sites across the entire human proteome, including proteins too d
Press release cover image

Oct 1, 2026

DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform

New capabilities enable researchers to analyse, characterise and prioritise antibody candidates at scale Integrated AI models and workflows support better informed decisions about which antibodies to progress experimentally LONDON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- DaltonTx, the decision engine for drug discovery, today announced the launch of advanced antibody discovery capabilities within the Dalton platform. The platform brings together antibody design, structure prediction and validation t
Press release cover image

Sep 30, 2026

Topos Bio Introduces Topos-2 and Topos-Bind to Combat “Undruggable” Diseases

Early testing showed that Topos-2 was nearly 4x closer to experimental ground-truth than the next-best model, and Topos-Bind was the only model able to predict how the shape of amyloid-beta, an Alzheimer's target, changes with drugsSAN FRANCISCO--(BUSINESS WIRE)--Topos Bio, an AI-powered biotechnology company, today introduced two new AI foundation models. The first is Topos-2, built to predict how intrinsically disordered proteins (IDPs), which are dynamic in nature, move and change shapes. The
Press release cover image

Sep 30, 2026

CUSABIO Expands Flexible Antibody Expression for AI-Driven Antibody Discovery

Flexible sequence counts, configurableexpression scales and optional binding validation support iterative antibodydiscovery programs.HOUSTON, Sept. 23, 2026 —CUSABIO announced the expansion of its flexible recombinant antibody expressionservice for AI-driven antibody discovery, offering biotechnology andpharmaceutical research teams configurable wet-lab support as antibodycandidates progress through successive discovery and optimization rounds.The service supports projects ranging froma single a
A laboratory pipette over antibody samples in a dimly lit lab

Sep 29, 2026

Ginkgo Datapoints, Apheris Announce Founding Members of Antibody Developability Consortium

Ginkgo Datapoints and Apheris have launched the Antibody Developability Consortium, aimed at enhancing the predictability of antibody manufacturability and developability risks for the pharmaceutical and biotech sectors.This new consortium has attracted founding members such as AbbVie, argenx, Lundbeck, and Takeda, with an open invitation for other companies to join. Each member will contribute proprietary antibody sequencing data to build what is anticipated to be the largest standardized datas
Press release cover image

Sep 29, 2026

CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today notes the announcement from Sarborg Limited regarding the filing of new intellectual property applying quantum sampling to disease biology and drug discovery. CDT holds 1,290 shares in Sarborg, representing 22.7% of the issued share capital. Sarborg’s latest capital raise was at $125,000 per share, implying a fully diluted valuation of approximately $709 m
Press release cover image

Sep 25, 2026

MarWell Bio Awarded DARPA Research Contract Under NODES Program to Advance the Next Generation of Predictive Biology

San Francisco,California — [September 25, 2026] — MarWell Bio Inc. today announced that it has been awardeda research contract under the Defense Advanced Research Projects Agency's(DARPA) [Network of Optimal Dynamic Energy Signatures (NODES)] program. As theprime performer, and in collaboration with the Gunner Laboratory at The CityCollege of New York, MarWell Bio is developing advanced computationalcapabilities to support DARPA's objective of predicting protein functiondirectly from amino acid
Press release cover image

Sep 25, 2026

Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND Clearance

SHANGHAI, Sept. 25, 2026 /PRNewswire/ -- Nutshell Therapeutics (Shanghai) Co., Ltd. ("Nutshell Therapeutics"), an innovative biotech company focused on AI-driven allosteric drug discovery, announced FDA IND clearance for NTS231, a covalent allosteric molecular glue degrader of NRF2, to launch clinical development in the United States.NTS231 is the first NRF2 degrader molecule from China and second globally to enter clinical development. This program represents a significant advancement in effort
Press release cover image

Sep 24, 2026

ACROBiosystems Introduces CHO-Direct and ACRO AIx to Accelerate AI-driven Drug Discovery

SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- Recently, ACROBiosystems unveiled its latest innovation portfolio—ACRO AIx, CHO-Direct and GlobalLifeShip cross border supply chain to respond the demand of AIDD era.As artificial intelligence becomes increasingly integrated into drug discovery, the design and screening of candidate molecules are becoming more efficient. Experimental validation is emerging as a critical link between computational predictions and R&D decisions. In AI-driven Drug Disco